Biotech company CytoSite Bio was developing a novel diagnostic radiopharmaceutical (a Granzyme B imaging agent) and recognized the agent’s significant scalability and potential for applications beyond its original purpose.
They wanted to evaluate the agent's potential as a companion diagnostic in immuno-oncology.
To achieve this, CytoSite sought out expert guidance to navigate the complex regulatory, clinical, and business challenges....